Last reviewed · How we verify
A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age
Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
Details
| Lead sponsor | Novartis Vaccines |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 33 |
| Start date | 2006-04 |
| Completion | 2006-08 |
Conditions
- Prevention of Meningococcal Infection
Interventions
- Meningococcal C conjugate vaccine
Primary outcomes
- Persistence of memory B cells in the blood at least one year after primary immunisation with MenC Vaccine at 2, 3 and 4 months of age, as determined by meningococcal C specific B-cell ELISPot assay or limiting dilution
Countries
United Kingdom